Non-alcoholic steatohepatitis (NASH): where are we now and where are we going?
Open Access
- 1 May 2002
- Vol. 50 (5) , 585-588
- https://doi.org/10.1136/gut.50.5.585
Abstract
Although non-alcoholic steatohepatitis (NASH) was considered relatively uncommon prior to the middle of the last decade, over the past three years there has been an explosion of studies on various aspects of NASH with one study reporting that after hepatitis C, NASH was the most common diagnosis in patients presenting largely with persistent abnormalities of liver function tests. The field of NASH has come a long way in a relatively short space of time. This article considers advances in knowledge that have arisen as a result of these studies and highlights areas for further work.Keywords
This publication has 34 references indexed in Scilit:
- Mitochondria in SteatohepatitisSeminars in Liver Disease, 2001
- Treatment of Nonalcoholic Fatty Liver: Present and Emerging TherapiesSeminars in Liver Disease, 2001
- Metformin in non-alcoholic steatohepatitisThe Lancet, 2001
- Nonalcoholic Fatty Liver DiseaseDiabetes, 2001
- Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serologyJournal of Hepatology, 2001
- Clinical Hepatology: Profile of An Urban, Hospital–Based PracticHepatology, 1996
- The natural history of nonalcoholic fatty liver: a follow-up study.1995
- The influence of fatty liver on insulin clearance and insulin resistance in non-diabetic Japanese subjects.1995
- Nonalcoholic steatohepatitis: An expanded clinical entityGastroenterology, 1994
- Liver in obesity.Gut, 1985